Hong Kong stock movement: MicroPort Medbot-B rises 17.45%, stock price boosted by new product approval and surge in orders

Hong Kong Stock Movement MicroPort Medbot-B rose 17.45%. Based on recent key news: On December 29, MicroPort Medbot-B's independently developed bronchoscopic surgical robot, the UniPath electronic bronchoscope surgical navigation system, received approval from the National Medical Products Administration. The approval of this product enhances the company's competitiveness in the surgical robot field, driving the stock price up. On December 28, MicroPort Medbot-B announced that the cumulative order volume of its core products in endoscopy, orthopedics, and vascular intervention has exceeded 230 units, with the Tumi endoscopic surgical robot ranking among the top two globally in order volume. The increase in order volume indicates strong market demand for its products, further supporting the rise in stock price. On December 28, MicroPort Medbot-B announced that the number of its approved products in the surgical robot field has increased to 7, becoming the first company globally to commercialize products in five major golden track categories. This achievement has boosted market confidence in the company, propelling the stock price upward. The demand in the surgical robot industry is strong, and market confidence is enhanced. Stocks with High Trading Volume in the Industry MicroPort Medical rose 2.75%, with a trading volume of HKD 89.57 million, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and specific reasons need further observation. MicroPort Neuroscience rose 2.91%, with a trading volume of HKD 12.72 million, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and specific reasons need further observation. Xianjian Technology had a trading volume of HKD 7.36 million. Based on recent news: On December 26, in terms of international expansion, the focus is on product research and sales progress in the European and American markets. Due to previous layouts of many companies in overseas channels and production bases, the overseas market growth of the sector is expected to accelerate by 2026. This news has boosted market confidence, driving Xianjian Technology's stock price up. On December 26, low-value consumable companies are accelerating their layout of overseas production bases to restore and expand their competitiveness in the U.S. market. After the top companies' overseas bases are put into production by 2026, they are expected to quickly regain the U.S. market share lost due to tariff policies, achieving clear profit increments. This positive expectation further propelled Xianjian Technology's stock price upward. On December 26, the internationalization of home medical devices has become the core strategy for domestic listed companies in this sector. Leading companies are accelerating their business expansion overseas through mergers and acquisitions and overseas product registrations. By 2026, some companies are expected to gradually enter the harvest period in overseas markets and innovative products, with growth expected to accelerate. As a leading enterprise in the industry, Xianjian Technology's stock price performed strongly due to this news. The overall industry performance is good, and the advancement of internationalization strategies is significant. Stocks with High Market Capitalization in the Industry Angelalign fell 0.49%. Based on recent key news: On December 26th, Angelalign held an MDR-CE certificate awarding ceremony in Shanghai. This event indicates that the company has made progress in medical device certification, which may have a positive impact on its future market expansion. However, the stock price did not reflect this good news, showing that the market remains cautious about short-term performance improvements. Source: Company official WeChat There are no other important news recently. The medical device industry faces risks from policy changes